FYI: The healthcare sector will continue to see political attention in 2018 with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation. Industry experts believe the Republicans will also continue to take further actions on Obamacare provisions, seeking new changes and cost saving measures. Meanwhile, the lower tax rate will benefit all of corporate America and offer a significant advantage for pharmaceutical research and development.
Happy New Years,
Ted
https://www.investopedia.com/articles/etfs/top-pharmaceutical-etfs/?partner=YahooSA&yptr=yahoo
